Clinical trials of Sputnik V among adolescents aged 12-17 start in Moscow

Officials have blamed the Delta variant for the sudden surge in COVID-19 infections in Russia.

According to city officials, Russia’s COVID-19 vaccine Sputnik V’s clinical trials among teenagers aged 12-17 began in the capital city of Moscow on July 5.

Anastasia Rakova, the Deputy Mayor, stated the 100 recruited volunteers had not been infected with COVID-19 in the past and don’t suffer from any health issue that would prevent them from receiving the shots. Moreover, the youth will receive a smaller dose of Sputnik V vaccine as compared to the dose given to adults.


The decision comes after the rise of fresh COVID-19 cases in the Eurasian country as well as the decreased speed of vaccination.  Only 16 per cent i.e 23 million of Russia’s 146 million population have been administered with at least one dose of COVID-19 vaccine since the start of the vaccination drive i.e. January 2021.

The Mayor of Moscow Sergey Sobyanin has called the highly contagious Delta variant of the virus, first detected in India, responsible for 90 per cent of new infections reported in the capital city.

The authorities of Russia have registered more than 5.2 million confirmed coronavirus cases and 1,38,579 deaths till now.

On July 3 (Saturday), the country had recorded 697 deaths in a single day as Russia is witnessing a surge of COVID-19 infections. On Monday, 24,353 fresh cases were reported along with 654 fatalities.